Tamoxifen treatment for advanced pancreatic tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the efficacy and safety of tamoxifen, a selective estrogen receptor modulator, in patients with advanced solid pseudopapillary tumors of the pancreas. The study focuses on individuals with unresectable or metastatic disease, where standard treatment options are limited. Participants will receive tamoxifen at a dosage of 20 mg, and the trial aims to determine its impact on tumor progression and patient outcomes. The study is particularly relevant for those with hormone receptor-positive tumors, as previous case reports suggest potential benefits.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age 14-80 years.
2. Histologically confirmed advanced SPTP with ER/PR+.
3. Advanced disease:

   * Unresectable primary tumor or distant metastasis (liver, lung, peritoneum, etc.).
   * Recurrent or refractory after prior surgery/systemic therapy.
4. ≥1 measurable lesion.
5. ECOG performance status 0-2.
6. Life expectancy ≥1 month.
7. Able to comply with study visits and oral medication.

Exclusion Criteria:

1. Non-SPTP pathology.
2. Active gastrointestinal inflammation/infection (e.g., pancreatitis).
3. Pregnancy/lactation.
4. Severe organ dysfunction (renal, cardiac, hepatic, or pulmonary).
5. Uncontrolled comorbidities (e.g., CNS disorders, unstable angina).
6. Conditions compromising patient safety or data integrity.

Where it's running

• Shanghai Cancer Center
  Shanghai, China Recruiting

Study contacts

• Principal investigator: Guopei Luo Prof, MD — Shanghai Cancer Center
• Study coordinator: Huanyu Xia MD
• Email: xiahuanyu@fudanpci.org
• Phone: 86 21 64031446

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Energy needs after pancreatic surgery: measuring metabolism to guide nutrition

  This study tests how much energy patients need after pancreatic surgery and compares direct measurements with common estimating methods to see if standard formulas are accurate.

  Recruiting Evangelismos Hospital · Athens, Attica · NCT07703813

• Liquid biopsy biomarkers to detect and monitor pancreatic cancer

  Researchers test blood-based microRNA signals to see if they can identify pancreatic cancer risk or early disease in people with familial or hereditary risk or mucinous cysts.

  Recruiting Università Vita-Salute San Raffaele · Milan, MI · NCT07700992

• Indocyanine green–guided laparoscopic distal pancreatectomy vs standard approach for pancreatic body/tail lesions

  This trial tests whether using indocyanine green (ICG) fluorescence during laparoscopic distal pancreatectomy helps surgeons protect blood flow and structures, compared with the standard approach, in adults with pancreatic body or tail tumors.

  Recruiting Alexandria University · Alexandria · NCT07656571

• Pancreatic Surgery and New Diabetes Risk in Adults without Diabetes

  This study tests whether removing part or all of the pancreas during surgery affects blood sugar control and metabolism in adults who did not have diabetes before the operation.

  Recruiting Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Rome · NCT07608055

• Pancreatic Cancer Screen Test in Japan Using the Enzeavour Blood Assay

  This nationwide screening study in Japan tests the Enzeavour Pancreatic Cancer blood test in about 10,000 asymptomatic adults to see if it can help detect pancreatic cancer early.

  Recruiting at 69 sites Cosomil, Inc. · Nagakute, Aichi-ken and 68 other locations · NCT07605819

• NEO-Match nanomechanical testing of pancreatic tumor samples

  This will test whether the NEO-Match® nanomechanical test on biopsy tissue can help predict response to pre-surgery treatment and detect cancer in people with suspected pancreatic tumors.

  Recruiting Artidis Ag · Tampa, Florida · NCT07542041

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.